Timothy Bailey, MD
Endocrinology, Diabetes & Metabolism · Escondido, CANPI 1194800052
Payments from drug & device makers
Across 1,634 payments — averaging $13,652 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$7.7M
- Senseonics, Incorporated$6.2M
- Medtronic$2.9M
- Eli Lilly$2.2M
- Abbott$723K
- Sanofi US Services Inc.$630K
- plus $2M from 26 others
Across 37 payments — averaging $1296.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$27K
- Sanofi-aventis U.S. LLC$21K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 124 | $7,718,276 |
| Senseonics, Incorporated | 85 | $6,162,568 |
| Medtronic(2 entities) | 154 | $2,895,032 |
| Eli Lilly | 62 | $2,159,547 |
| Abbott | 198 | $722,577 |
| Sanofi US Services Inc. | 197 | $629,523 |
| Roche Diabetes Care, Inc. | 16 | $562,838 |
| AstraZeneca | 18 | $459,815 |
| Novo Nordisk AS | 546 | $360,542 |
| Genentech, Inc. | 42 | $132,045 |
| Sanofi-aventis U.S. LLC | 62 | $120,431 |
| Mannkind Corporation | 10 | $106,609 |
| Kowa Research Institute, Inc. | 35 | $90,566 |
| Lexicon Pharmaceuticals, Inc. | 4 | $52,338 |
| F. Hoffmann-la Roche AG | 13 | $47,393 |
| Amgen(2 entities) | 4 | $32,855 |
| Roche Diabetes Care GmbH | 6 | $19,018 |
| Novo Nordisk | 20 | $18,837 |
| Cequr Corporation | 3 | $14,607 |
| Bigfoot Biomedical Inc | 8 | $697 |
| Insulet Corporation | 6 | $193 |
| Lilly USA, LLC | 6 | $89 |
| Bayer | 2 | $62 |
| Roche Diagnostics Corporation | 1 | $60 |
| Ascendis Pharma Endocrinology Inc | 2 | $58 |
| Ascensia Diabetes Care US Inc. | 2 | $37 |
| Madrigal Pharmaceuticals | 2 | $33 |
| BETA Bionics, Inc. | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $11 |
| Travere Therapeutics, Inc. | 2 | $2 |
How this compares
$22,306,727 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Escondido
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
- Dan StrejaWest Hills$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.